Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Talampanel.

John F Howes1, Cynthia Bell

  • 1Department of New Drug Development, IVAX Research, Inc., Miami, Florida 33137, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary

Talampanel, an AMPA receptor inhibitor, shows promise as an anticonvulsant. Clinical studies demonstrate its effectiveness in reducing seizures for patients with difficult-to-treat epilepsy.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canine Maxillofacial Parosteal Osteosarcoma: A Retrospective Case Evaluation in 10 Dogs.

Journal of veterinary dentistry·2026
Same author

Estimating global public health security preparedness capacity: The contribution of SPAR and JEE.

Dialogues in health·2026
Same author

Surgical outcomes in canine lymphoplasmacytic stomatitis: a retrospective study of 42 dogs (2012-2022).

Frontiers in veterinary science·2025
Same author

Sialolith in a minor salivary gland of an 8-year-old European domestic shorthair cat: a case report.

Veterinary research communications·2025
Same author

The dynamic preparedness metric: results from a global and regional analysis of health emergency preparedness.

BMC public health·2025
Same author

Odontomas in Cats: A Case Series.

Journal of veterinary dentistry·2025

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Talampanel is a novel anticonvulsant drug.
  • It functions as an allosteric inhibitor of the AMPA receptor, a key player in neuronal excitation.

Purpose of the Study:

  • To evaluate the efficacy of talampanel in epilepsy and neuroprotection.
  • To assess its effectiveness in reducing seizures in patients with refractory partial seizures.

Main Methods:

  • Preclinical studies in animal models of epilepsy and neuroprotection.
  • Clinical trials involving patients with refractory partial seizures.

Main Results:

  • Talampanel demonstrated a broad spectrum of action in animal models.
  • Clinical data indicated a reduction in seizure frequency in treated patients.

Conclusions:

  • Talampanel is a promising anticonvulsant agent.
  • Its effectiveness in managing refractory partial seizures warrants further investigation.